Supernus Pharmaceuticals, Inc. Healthcare | Drugs - Generic | USA Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products for the treatment of epilepsy include Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate. The company products candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase IIb clinical trials for the treatment of ADHD. It is also developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Just had a golden cross (50 sma crossing above 200 sma), and confirmed it on Friday moving +6% on 1.5x normal volume. Friday is usually a balancing day with options expiring. A generic drug maker with 73% EPS growth for the next 5 years. So even though its P/E ~ 50, its PEG is only 0.67.
http://www.fool.com/investing/general/2016/05/12/3-cheap-growth-stocks-you-can-buy-right-now.aspx Never heard of those drugs myself. But ADHD drugs in the pipeline sounds intriguing. Currently SUPN has annual sales of $160M.
Still waiting for these guys to file a quarterly earnings report. It's been a month since they were warned.
